In the final part of his conversation with Pharmaceutical Executive, Ken Keller discusses what his expectations are following the healthcare conference.
Ken Keller
Advertisement
Articles by Ken Keller
Ken Keller, Daiichi Sankyo’s head of global oncology and CEO of US operations, discusses the importance of bringing quality data to the JP Morgan Healthcare Conference.
Daiichi Sankyo’s US CEO and head of global oncology Ken Keller explains what his expectations are for JP Morgan prior to the conference.
Advertisement
Latest Updated Articles
Why Was There Such an Emphasis on Data Collection at this Year's Conference?Published: January 19th 2026 | Updated:
What is Daiichi Sankyo’s Strategy for Preparing for the JP Morgan Healthcare Conference?Published: January 16th 2026 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Releases 2025 Financial Report and 2026 Sales and Operations Profit Outlook
2
Veradermics Raises $256 Million in Upsized Initial Public Offering
3
Novartis’ Q4 Recap Shows Signs of Looming Patent Cliff
4
From OR to Office: How Workflow Change and AI Are Reshaping MedTech Adoption
5